The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics

被引:71
作者
Blank, A. [1 ,2 ]
Eidam, A. [1 ,2 ]
Haag, M. [3 ,4 ]
Hohmann, N. [1 ,2 ]
Burhenne, J. [1 ,2 ]
Schwab, M. [3 ,4 ,5 ,6 ]
van de Graaf, S. F. J. [7 ,8 ]
Meyer, M. R. [1 ,9 ]
Maurer, H. H. [9 ]
Meier, K. [1 ,2 ]
Weiss, J. [1 ,2 ]
Bruckner, T. [10 ]
Alexandrov, A. [11 ]
Urban, S. [2 ,12 ]
Mikus, G. [1 ,2 ]
Haefeli, W. E. [1 ,2 ]
机构
[1] Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany
[2] German Ctr Infect Res DZIF, Heidelberg Partner Site, Heidelberg, Germany
[3] Univ Tubingen, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[4] German Ctr Infect Res DZIF, Tubingen Partner Site, Tubingen, Germany
[5] Univ Hosp Tubingen, Dept Clin Pharmacol, Tubingen, Germany
[6] Univ Tubingen, Dept Pharm & Biochem, Tubingen, Germany
[7] Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Amsterdam, Netherlands
[8] Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[9] Saarland Univ, Expt & Clin Toxicol, Homburg, Germany
[10] Heidelberg Univ Hosp, Inst Med Biostat & Med Informat, Heidelberg, Germany
[11] Myr GmbH, Bad Homburg, Germany
[12] Heidelberg Univ Hosp, Dept Infect Dis, Mol Virol, Heidelberg, Germany
关键词
HEPATITIS-B; SUBSTRATE MIDAZOLAM; DISOPROXIL FUMARATE; VIRUS; ENTRY; POLYPEPTIDE; TRANSPORTERS; RECEPTORS; ENZYMES;
D O I
10.1002/cpt.744
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Myrcludex B acts as a hepatitis B and D virus entry inhibitor blocking the sodium taurocholate cotransporting polypeptide (SLC10A1). We investigated the effects of myrcludex B on plasma bile acid disposition, tenofovir pharmacokinetics, and perpetrator characteristics on cytochrome P450 (CYP) 3A. Twelve healthy volunteers received 300 mg tenofovir disoproxil fumarate orally and 10 mg subcutaneous myrcludex B. Myrcludex B increased total plasma bile acid exposure 19.2-fold without signs of cholestasis. The rise in conjugated bile acids was up to 124-fold (taurocholic acid). Coadministration of tenofovir with myrcludex B revealed no relevant changes in tenofovir pharmacokinetics. CYP3A activity slightly but significantly decreased by 29% during combination therapy. Myrcludex B caused an asymptomatic but distinct rise in plasma bile acid concentrations and had no relevant impact on tenofovir pharmacokinetics. Changes in CYP3A activity might be due to alterations in bile acid signaling. Long-term effects of elevated bile acids will require critical evaluation.
引用
收藏
页码:341 / 348
页数:8
相关论文
共 41 条
[21]   Bile Acids Regulate Cardiovascular Function [J].
Khurana, Sandeep ;
Raufman, Jean-Pierre ;
Pallone, Thomas L. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2011, 4 (03) :210-218
[22]   Inhibitors of Hepatitis B Virus Attachment and Entry [J].
Lempp, Florian A. ;
Urban, Stephan .
INTERVIROLOGY, 2014, 57 (3-4) :151-157
[23]  
Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
[24]   Bile acids: Chemistry, physiology, and pathophysiology [J].
Monte, Maria J. ;
Marin, Jose J. G. ;
Antelo, Alvaro ;
Vazquez-Tato, Jose .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (07) :804-816
[25]  
MYR GmbH, 2014, MYRCL B INV BROCH 5
[26]   Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes [J].
Ni, Yi ;
Lempp, Florian A. ;
Mehrle, Stefan ;
Nkongolo, Shirin ;
Kaufman, Christina ;
Faelth, Maria ;
Stindt, Jan ;
Koeniger, Christian ;
Nassal, Michael ;
Kubitz, Ralf ;
Sueltmann, Holger ;
Urban, Stephan .
GASTROENTEROLOGY, 2014, 146 (04) :1070-U301
[27]   Binding of Hepatitis B Virus to Its Cellular Receptor Alters the Expression Profile of Genes of Bile Acid Metabolism [J].
Oehler, Nicola ;
Volz, Tassilo ;
Bhadra, Oliver D. ;
Kah, Janine ;
Allweiss, Lena ;
Giersch, Katja ;
Bierwolf, Jeanette ;
Riecken, Kristoffer ;
Pollok, Joerg M. ;
Lohse, Ansgar W. ;
Fehse, Boris ;
Petersen, Joerg ;
Urban, Stephan ;
Luetgehetmann, Marc ;
Heeren, Joerg ;
Dandri, Maura .
HEPATOLOGY, 2014, 60 (05) :1483-1493
[28]   Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome p450 [J].
Schuetz, EG ;
Strom, S ;
Yasuda, K ;
Lecureur, V ;
Assem, M ;
Brimer, C ;
Lamba, J ;
Kim, RB ;
Ramachandran, V ;
Komoroski, BJ ;
Venkataramanan, R ;
Cai, HB ;
Sinal, CJ ;
Gonzalez, FJ ;
Schuetz, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :39411-39418
[29]  
Sehayek E, 2001, J LIPID RES, V42, P1250
[30]  
SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414